Solriamfetol 300 mg
SOL-MDD-301
Phase 3 small_molecule completed
Quick answer
Solriamfetol 300 mg for Major Depressive Disorder is a Phase 3 program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Axsome Therapeutics
- Indication
- Major Depressive Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed